Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Diagn Microbiol Infect Dis. 2019 Jul 30;95(4):114874. doi: 10.1016/j.diagmicrobio.2019.114874

Table 2.

Urine-specific antibiogram by organism type, including Escherichia coli.

Proportion susceptible, column % P valuea
Gram- Gram- All vs. All vs. Gram-
All positives negatives E. coli Gram- Gram- All vs. negatives
Antimicrobial (n = 2494) (n = 946) (n = 1548) (n = 679) positives negatives E. coli vs. E. coli
amikacin 62 0 100 100 <.001 <.001 <.001 .10
ampicillin 39 54 31 56 <.001 <.001 <.001 <.001
ampicillin/sulbactam 59 73 51 65 <.001 <.001 .006 <.001
penicillin 39 53 31 56 <.001 <.001 <.001 <.001
cefazolin 55 37 65 90 <.001 <.001 <.001 <.001
cefepime 72 37 94 95 <.001 <.001 <.001 .48
cefoxitin 56 37 67 90 <.001 <.001 <.001 <.001
ceftazidime 62 10 93 94 <.001 <.001 <.001 .67
ceftriaxone 65 37 83 94 <.001 <.001 <.001 <.001
ciprofloxacin 61 37 76 72 <.001 <.001 <.001 .04
clindamycin 14 38 0 0 <.001 <.001 <.001 N/Af
ertapenem 69 37 88 100 <.001 <.001 <.001 <.001
erythromycin 12 33 0 0 <.001 <.001 <.001 N/A
fosfomycin 100/50b 95 100 92 100 <.001 <.001 <.001 <.001
fosfomycin 0c 81 86 79 100 .003 .03 <.001 <.001
gentamicin 74 43 93 92 <.001 <.001 <.001 .22
imipenem 89 75 97 100 <.001 <.001 <.001 <.001
levofloxacin 65 47 75 72 <.001 <.001 <.001 .11
linezolid 37 98 0 0 <.001 <.001 <.001 N/A
moxifloxacin 68 56 75 72 <.001 <.001 .047 .11
nitroflirantoin 64 82 53 91 <.001 <.001 <.001 <.001
oxacillin 13 35 0 0 <.001 <.001 <.001 N/A
piperacillin/tazobactam 86 73 94 98 <.001 <.001 <.001 <.001
quinupristin/dalfopristin 24 62 0 0 <.001 <.001 <.001 N/A
tobramycin 58 0 94 91 <.001 <.001 <.001 .009
trimethoprim/sulfamethoxazole 100d 78 88 72 77 <.001 <.001 .58 .02
trimethoprim/sulfamethoxazole 0e 57 33 72 77 <.001 <.001 <.001 .02
vancomycin 37 98 0 0 <.001 <.001 <.001 N/A
a

P values < .05 (by Chi squared test) are shown in boldface.

b

fosfomycin 100/50: Proteus species imputed as 100% susceptible, Staphylococcus saprophyticus imputed as 100% susceptible, Pseudomonas aeruginosa imputed as 50% susceptible.

c

fosfomycin 0: Proteus species imputed as 0% susceptible, Staphylococcus saprophyticus imputed as 0% susceptible, Pseudomonas aeruginosa imputed as 0% susceptible.

d

trimethoprim/sulfamethoxazole 100: Enterococcus species imputed as 100% susceptible.

e

trimethoprim/sulfamethoxazole 0: Enterococcus species imputed as 0% susceptible.

f

N/A: not applicable (0% prevalence in both groups).